A Case Report of Bezoar-Induced Small Bowel Obstruction: A Potential Surgical Complication of Semaglutide.
Cureus · 2025
Last updated 2026-08-28| Journal | Cureus, 2025 |
|---|---|
| Citations | 0 |
| Molecules | semaglutide |
Abstract
Bezoars are an uncommon but recognised cause of small bowel obstruction (SBO) and are difficult to differentiate preoperatively from other aetiologies. We report a rare case of acute SBO due to a bezoar in a 65-year-old woman who had been on semaglutide, a Glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight loss. She presented with a four-day history of abdominal pain, distension, nausea, and vomiting. Imaging confirmed SBO. Following unsuccessful nonoperative management, she underwent diagnostic laparoscopy and laparoscopic resection of a jejunal segment containing a large phytobezoar. We postulated that semaglutide-induced gastroparesis and slow intestinal transit may have contributed to bezoar formation and subsequent bowel obstruction. This case highlights a rare but important surgical adverse effect, particularly in patients receiving GLP-1 receptor agonists who present with bowel obstruction.
Verbatim abstract via PubMed 41431486 ↗
Related research
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.